XY Capital Ltd Invests $6.84 Million in BeiGene, Ltd. (NASDAQ:BGNE)

XY Capital Ltd acquired a new stake in BeiGene, Ltd. (NASDAQ:BGNE) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 30,464 shares of the company’s stock, valued at approximately $6,839,000. BeiGene accounts for 2.3% of XY Capital Ltd’s investment portfolio, making the stock its 6th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Capital International Investors increased its position in shares of BeiGene by 11.5% in the first quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after buying an additional 727,556 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after acquiring an additional 117,905 shares during the last quarter. Capital International Inc. CA increased its holdings in BeiGene by 6.0% during the 1st quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock valued at $134,240,000 after acquiring an additional 48,615 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in BeiGene during the second quarter worth about $54,412,000. Finally, Capital Group Private Client Services Inc. lifted its holdings in shares of BeiGene by 5.9% in the first quarter. Capital Group Private Client Services Inc. now owns 208,800 shares of the company’s stock valued at $32,654,000 after purchasing an additional 11,579 shares in the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BGNE shares. JMP Securities assumed coverage on shares of BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective for the company. JPMorgan Chase & Co. raised their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd. Finally, Citigroup upped their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $246.21.

Insider Activity

In other BeiGene news, SVP Chan Henry Lee sold 1,202 shares of BeiGene stock in a transaction on Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $237.10, for a total value of $284,994.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John Oyler sold 6,175 shares of BeiGene stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. Insiders sold a total of 23,070 shares of company stock valued at $4,901,050 in the last 90 days. 7.43% of the stock is currently owned by insiders.

BeiGene Trading Down 0.7 %

Shares of BGNE opened at $205.47 on Friday. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $248.16. The company has a market capitalization of $20.00 billion, a PE ratio of -40.45 and a beta of 0.63. The stock has a fifty day moving average of $212.41 and a two-hundred day moving average of $180.40. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The firm had revenue of $929.20 million for the quarter, compared to the consensus estimate of $810.34 million. During the same period in the prior year, the business posted ($3.64) earnings per share. The firm’s revenue for the quarter was up 56.1% compared to the same quarter last year. As a group, analysts forecast that BeiGene, Ltd. will post -5 EPS for the current year.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.